Literature DB >> 10482095

Systemic findings associated with central serous chorioretinopathy.

M K Tittl1, R F Spaide, D Wong, E Pilotto, L A Yannuzzi, Y L Fisher, B Freund, D R Guyer, J S Slakter, J A Sorenson.   

Abstract

PURPOSE: To determine systemic factors associated with central serous chorioretinopathy.
METHODS: In a retrospective study, 230 consecutive patients with central serous chorioretinopathy examined in a referral setting were compared with a historical gender-matched and age-matched control group of 230 patients with ocular findings who were examined in the same referral setting.
RESULTS: The median age of the patients was 49.8 years, and of the control subjects, 50.0 years. The male-female ratio for both groups was 2.7:1. Patients with central serous chorioretinopathy were more likely to use psychopharmacologic medications (odds ratio = 2.6; 95% confidence interval = 1.30 to 5.19; P = .0049) and corticosteroids (odds ratio = 3.17; 95% confidence interval = 1.30 to 7.70; P = .0067) and were more likely to have hypertension (odds ratio = 2.25; 95% confidence interval = 1.39 to 3.63; P = .0008) than were the control subjects.
CONCLUSIONS: This study identified psychopharmacologic medication use, corticosteroid use, and hypertension as factors associated with central serous chorioretinopathy. These findings reinforce the concept that stress and adaptations to stress play a role in this disorder. The findings of possible associations between central serous chorioretinopathy and both hypertension and corticosteroid usage suggest that these modifiable factors may influence morbidity of central serous chorioretinopathy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10482095     DOI: 10.1016/s0002-9394(99)00075-6

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  91 in total

1.  Central serous chorioretinopathy.

Authors:  J M Jumper
Journal:  Br J Ophthalmol       Date:  2003-06       Impact factor: 4.638

2.  Evaluation of Choroidal Thickness and Volume during the Third Trimester of Pregnancy using Enhanced Depth Imaging Optical Coherence Tomography: A Pilot Study.

Authors:  Renata T Rothwell; Dália M Meira; Marisa A Oliveira; Lígia F Ribeiro; Sofia L Fonseca
Journal:  J Clin Diagn Res       Date:  2015-08-01

3.  Effect of a topical nonsteroidal anti-inflammatory agent (0.1 % pranoprofen) on acute central serous chorioretinopathy.

Authors:  Seoung Hyun An; Yoon Hyung Kwon
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-11-09       Impact factor: 3.117

4.  Response of central serous chorioretinopathy evaluated by multimodal retinal imaging.

Authors:  R Sacconi; G Baldin; A Carnevali; L Querques; A Rabiolo; G Marchini; F Bandello; G Querques
Journal:  Eye (Lond)       Date:  2018-01-05       Impact factor: 3.775

5.  [Central serous chorioretinopathy--retinal function and morphology: microperimetry and optical coherence tomography].

Authors:  C Springer; H E Völcker; K Rohrschneider
Journal:  Ophthalmologe       Date:  2006-09       Impact factor: 1.059

6.  Finasteride is effective for the treatment of central serous chorioretinopathy.

Authors:  E Moisseiev; A J Holmes; A Moshiri; L S Morse
Journal:  Eye (Lond)       Date:  2016-04-08       Impact factor: 3.775

7.  En face enhanced-depth swept-source optical coherence tomography features of chronic central serous chorioretinopathy.

Authors:  Daniela Ferrara; Kathrin J Mohler; Nadia Waheed; Mehreen Adhi; Jonathan J Liu; Ireneusz Grulkowski; Martin F Kraus; Caroline Baumal; Joachim Hornegger; James G Fujimoto; Jay S Duker
Journal:  Ophthalmology       Date:  2013-11-26       Impact factor: 12.079

8.  Comparison of two mineralcorticosteroids receptor antagonists for the treatment of central serous chorioretinopathy.

Authors:  Francesco Pichi; Paola Carrai; Antonio Ciardella; Francine Behar-Cohen; Paolo Nucci
Journal:  Int Ophthalmol       Date:  2016-10-18       Impact factor: 2.031

9.  Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level.

Authors:  W-M Chan; D S C Lam; T Y Y Lai; B S M Tam; D T L Liu; C K M Chan
Journal:  Br J Ophthalmol       Date:  2003-12       Impact factor: 4.638

10.  Central serous chorioretinopathy after dacryocystorhinostomy operation on the same side.

Authors:  Lakshmikanta Mondal; Sayan Basu; Krishnapada Baidya; Gautam Bhaduri
Journal:  Indian J Ophthalmol       Date:  2009 Jan-Feb       Impact factor: 1.848

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.